SGLT2 inhibition and heart failure-current concepts

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Type 2 diabetes mellitus (T2DM) significantly increases the risk of cardiovascular (CV) conditions, notably heart failure (HF).
• Historically, treatments for T2DM lacked dedicated cardioprotective benefits against HF.
• The EMPA-REG OUTCOME trial marked a turning point, revealing empagliflozin's cardioprotective effects in T2DM patients.

Purpose of the Study:

• To review the impact of pharmacologic sodium-glucose cotransporter 2 (SGLT2) inhibitors on cardiac function.
• To explore the potential of SGLT2 inhibitors as a therapeutic option for heart failure, irrespective of diabetic status.

Main Methods:

• Review of pivotal clinical trials, including EMPA-REG OUTCOME and the CANVAS Program.
• Analysis of real-world evidence from studies like CVD-Real, examining dapagliflozin, empagliflozin, and canagliflozin.
• Synthesis of findings to evaluate the class effect of SGLT2 inhibition on HF.

Main Results:

• Empagliflozin demonstrated a notable 35% reduction in HF hospitalizations.
• Subsequent studies (CANVAS, CVD-Real) corroborated these cardioprotective benefits.
• Evidence suggests the benefits of SGLT2 inhibition for HF are a class effect, not drug-specific.

Conclusions:

• Pharmacologic SGLT2 inhibition has emerged as a promising therapeutic strategy for managing heart failure.
• The cardioprotective effects observed extend beyond glycemic control, indicating a broader CV benefit.
• SGLT2 inhibitors represent a potential new class of medications for HF treatment in both diabetic and non-diabetic individuals.